<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01169376</url>
  </required_header>
  <id_info>
    <org_study_id>ANBL10B1</org_study_id>
    <secondary_id>COG-ANBL10B1</secondary_id>
    <secondary_id>CDR0000681912</secondary_id>
    <secondary_id>NCI-2011-02246</secondary_id>
    <nct_id>NCT01169376</nct_id>
  </id_info>
  <brief_title>Biomarkers in Young Patients With Neuroblastoma</brief_title>
  <official_title>Therapeutically Applicable Research to Generate Effective Treatments (TARGET) for Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may&#xD;
      help doctors identify and learn more about biomarkers related to cancer.&#xD;
&#xD;
      PURPOSE: This research study is studying biomarkers in young patients with neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To discover the therapeutically relevant driver mutations in high-risk pediatric&#xD;
           neuroblastoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To identify a set of highly annotated neuroblastoma specimens (primary tumors and cell&#xD;
           lines) for comprehensive genomic analyses, validation studies, resequencing efforts, and&#xD;
           future functional assays.&#xD;
&#xD;
        -  To define genome-wide DNA copy number and allelic status in at least 300 high-risk and&#xD;
           50 low-risk neuroblastoma primary untreated tumors, and 30 human neuroblastoma-derived&#xD;
           cell lines.&#xD;
&#xD;
        -  To define the genome-wide methylation profile of neuroblastoma in a minimum of 200&#xD;
           high-risk cases.&#xD;
&#xD;
        -  To define the genome-wide microRNA expression profile of neuroblastoma in a minimum of&#xD;
           200 high-risk cases.&#xD;
&#xD;
        -  To define genome-wide RNA expression signatures, including splice variations, in the&#xD;
           same tumors and cell lines studied above.&#xD;
&#xD;
        -  To identify mutations in candidate therapeutic targets using a staged resequencing&#xD;
           strategy with ultimate genome-scale next generation resequencing of 3 genomes for 200&#xD;
           high-risk cases: the neuroblastoma genome and transcriptome as well as the paired&#xD;
           constitutional genome.&#xD;
&#xD;
        -  To characterize the relapsed high-risk neuroblastoma genome and epigenome.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Previously collected samples are analyzed to define the genome-wide DNA copy number and&#xD;
      allelic status; to define the genome-wide methylation profile of high-risk neuroblastoma&#xD;
      cases; to define the genome-wide microRNA expression profile of high-risk neuroblastoma&#xD;
      cases; to define the genome-wide RNA expression and relating gene expression to DNA copy&#xD;
      number and gene polymorphisms, DNA methylation, and microRNA expression; to resequence three&#xD;
      genomes: the neuroblastoma genome, the transcriptome, and the paired constitutional genome;&#xD;
      and to characterize the relapsed high-risk neuroblastoma genome and epigenome.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 300 tumor samples from patients with high-risk disease, 50&#xD;
      tumor samples from patients with low-risk primary neuroblastoma, and 30 human&#xD;
      neuroblastoma-derived cell lines will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Discovery of therapeutically relevant driver mutations</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of a set of neuroblastoma specimens for analyses</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genome-wide DNA copy number and allelic status</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genome-wide methylation profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genome-wide microRNA expression profile</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genome-wide RNA expression signatures</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of mutations in candidate therapeutic targets</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of the relapsed high-risk neuroblastoma genome and epigenome</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Neuroblastoma</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA methylation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNA analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>comparative genomic hybridization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymorphism analysis</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients registered on the COG-ANBL00B1 Neuroblastoma Biology Study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Registered on the COG-ANBL00B1 Neuroblastoma Biology Study or its CCG or POG precursor&#xD;
&#xD;
          -  Sufficient high-quality tumor material available for the proposed studies meeting the&#xD;
             following criteria:&#xD;
&#xD;
               -  Tissue histopathologic review with &gt; 70% tumor cells in sections adjacent to&#xD;
                  areas used for nucleic acid preparation&#xD;
&#xD;
               -  Matched normal cells (blood or uninvolved bone marrow) available&#xD;
&#xD;
               -  ≥ 5 μg DNA available&#xD;
&#xD;
               -  ≥ 5 μg RNA available&#xD;
&#xD;
               -  ≥ 200 mg tissue available&#xD;
&#xD;
          -  Tumor samples must meet 1 of the following criteria:&#xD;
&#xD;
               -  High-risk tumor&#xD;
&#xD;
                    -  With or without MYCN amplification&#xD;
&#xD;
                    -  With or without tumor progression or relapse (during ≥ 2.5 years of follow&#xD;
                       up)&#xD;
&#xD;
                    -  Patients aged 18 months to 5 years&#xD;
&#xD;
               -  Low-risk tumor&#xD;
&#xD;
                    -  Primary neuroblastoma&#xD;
&#xD;
                    -  Stage I disease (completely resected)&#xD;
&#xD;
                    -  No event in ≥ 3 years of follow up&#xD;
&#xD;
               -  Cell lines representing diverse high-risk genetics including with or without MYCN&#xD;
                  amplification and clinical course (at diagnosis or after relapse)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M. Maris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>July 23, 2010</study_first_submitted>
  <study_first_submitted_qc>July 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2010</study_first_posted>
  <last_update_submitted>May 17, 2016</last_update_submitted>
  <last_update_submitted_qc>May 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>disseminated neuroblastoma</keyword>
  <keyword>localized resectable neuroblastoma</keyword>
  <keyword>localized unresectable neuroblastoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

